Cetuximab Rechallenge Study

Summary

To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.

Timeline

Start

2013-04-24

Primary completion

2020-04-07

Completion

2020-04-07

Drugs

Indications